|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/26 | |
| A61P 3/04 |
| (11) | Patento numeris | 2866825 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13737808.9 |
| Europos patento paraiškos padavimo data | 2013-06-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-05-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-04-08 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2013/063004 |
| Data | 2013-06-21 |
| (87) | Numeris | WO 2014/005858 |
| Data | 2014-01-09 |
| (30) | Numeris | Data | Šalis |
| 12174535 | 2012-07-01 | EP | |
| 201261694837 P | 2012-08-30 | US | |
| 12186781 | 2012-10-01 | EP | |
| 201261708162 P | 2012-10-01 | US |
| (72) |
JENSEN, Christine Bj rn, DK
RASMUSSEN, Mads Frederik, DK
ZDRAVKOVIC, Milan, DK
KRISTENSEN, Peter, DK
|
| (73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
| (54) | USE OF LONG-ACTING GLP-1 PEPTIDES |
| USE OF LONG-ACTING GLP-1 PEPTIDES |